1. Home
  2. CRNX vs RH Comparison

CRNX vs RH Comparison

Compare CRNX & RH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$84.97

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo RH

RH

RH

HOLD

Current Price

$146.61

Market Cap

3.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
RH
Founded
2008
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Specialty Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.5B
IPO Year
2018
2011

Fundamental Metrics

Financial Performance
Metric
CRNX
RH
Price
$84.97
$146.61
Analyst Decision
Strong Buy
Hold
Analyst Count
8
14
Target Price
$76.75
$167.00
AVG Volume (30 Days)
2.4M
536.5K
Earning Date
05-07-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
74.31
EPS
N/A
N/A
Revenue
$1,039,000.00
$1,193,046,000.00
Revenue This Year
$720.10
$8.39
Revenue Next Year
$184.67
$9.44
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.52
52 Week Low
$32.30
$106.30
52 Week High
$85.01
$256.78

Technical Indicators

Market Signals
Indicator
CRNX
RH
Relative Strength Index (RSI) 89.88 39.40
Support Level $83.47 $138.99
Resistance Level N/A $161.18
Average True Range (ATR) 0.12 7.28
MACD -0.86 -1.55
Stochastic Oscillator 93.85 18.39

Price Performance

Historical Comparison
CRNX
RH

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About RH RH

RH is a luxury furniture and lifestyle retailer primarily operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories, including furniture, lighting, textiles, bath, decor, and is growing the presence of its hospitality business with 26 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Estates and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade via expanding abroad, its World of RH digital platform (highlighting offerings outside of home furnishings), and offerings in architecture, media, and more.

Share on Social Networks: